MEDICINA
Departamento
Jagiellonian University
Cracovia, PoloniaPublicaciones en colaboración con investigadores/as de Jagiellonian University (21)
2024
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2022
-
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study
European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316
-
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors
American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884
2021
-
Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry
ESC Heart Failure, Vol. 8, Núm. 1, pp. 95-105
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
-
Genetically determined telomere length and multiple myeloma risk and outcome
Blood Cancer Journal, Vol. 11, Núm. 4
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2019
-
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Leukemia
-
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811
2018
-
The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: Baseline data and contemporary management of adult patients with cardiomyopathies
European Heart Journal, Vol. 39, Núm. 20, pp. 1784-1793
2017
-
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134
2016
-
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis
Oncotarget, Vol. 7, Núm. 37, pp. 59029-59048